뉴스정보

정보광장

COVID-19 Main protease inhibitor 관련 특허 24건 정리 Review

작성자
관리자
작성일
2021-12-29 14:49
조회
350
2021년 6월말까지 출원된 COVID-19 Main protease inhibitor 관련된 특허 24건을 정리한 Review 논문입니다.

저해제를 구조별로 정리하고 active site (Cys-145) binding mode에 대한 설명이 포함되어 있습니다.

A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors

ChemMedChem 2021, 16, ASAP.

<논문바로가기>

<Abstract>

The severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) pandemic is an unprecedented global health emergency causing more than 4.2 million fatalities as of 30 July 2021. Only three antiviral therapies have been approved or granted emergency use authorization by the FDA. The SARS-CoV-2 3CL protease (3CLpro) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis, although no inhibitors have been approved. This patent review discusses SARS coronavirus 3CLpro inhibitors that have been filed up to 30 July 2021, giving an overview on the types of inhibitors that have generated commercial interest, especially amongst drug companies. Insights into the common structural motifs required for active site binding is also discussed.